Anita Kumar

1 month ago | ascopubs.org | Toby Eyre |Anita Kumar |Steven Le Gouill

Mantle cell lymphoma (MCL) represents a relatively uncommon, heterogeneous lymphoma associated with limited overall survival. Targeting of the B-cell receptor pathway in relapsed disease with covalent Bruton tyrosine kinase (cBTK) inhibition has been demonstrated to be highly effective with cBTK inhibitor monotherapy, an established standard of care in relapsed MCL.

Oct 13, 2024 | nature.com | Jennifer K Lue |Alexander P Boardman |Steven Horwitz |Andrew M. Intlekofer |Anita Kumar |Ariela Noy | +4 more

Dear Editor,High-grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements (HGBCL-DH/TH) is a group of aggressive lymphomas that are associated with poor outcomes when treated with R-CHOP [1, 2]. Conflicting data exists regarding the outcomes of HGBCL with MYC and BCL2 rearrangements (DH-BCL2) as compared to HGBCL with MYC and BCL6 translocations (DH-BCL6) [3,4,5,6].

Jul 23, 2024 | orlandosentinel.com | Anita Kumar

New College of Florida overpaid faculty and administrators, accidentally paid vendors more than once and failed to collect more than $160,000 in student payments, according to a state report chronicling the school’s recent financial activities in recent years. The practices were among several negative findings — including violations of state law — in the state auditor general’s most recent operational audit of the university.

Feb 26, 2024 | targetedonc.com | Anita Kumar

Soon after mantle cell lymphoma (MCL) was recognized as a distinct subtype of B-cell non-Hodgkin lymphoma in 1992, researchers began to investigate the clinical outcomes of patients, noting the wide spectrum of outcomes that we still observe today. Refining our ability to prognosticate patients with MCL has been a major effort all the while using such information to inform treatment decisions and understanding the underlying disease biology of MCL.

Feb 12, 2024 | medium.com | Anita Kumar

Access the best member-only stories. Support independent authors. Listen to audio narrations. Join the Partner Program and earn for your writing. Try for $5/month